TickerTalks
Browse all tickers →
TickerTalks›$ILMN
ILILMN

Illumina, Inc.

$ILMN·$28B·Medical - Diagnostics & Research·Healthcare
$190.89-0.9%YTD+54.6%1Y+90.7%
Mentions · last 7 days
2026-08-08: 2 posts2026-08-09: 3 posts2026-08-10: 16 posts2026-08-11: 8 posts2026-08-12: 6 posts2026-08-13: 7 posts2026-08-14: 7 posts49+13%
Price updated 1d ago·X counts updated 1d ago
ILILMN
$ILMNIllumina, Inc.
$190.89-0.91%49 posts+13%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Today's AI verdict on what's driving $ILMN, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Proven numbersAcceleratingAI verdict · as of 2026-08-14

The move is getting stronger, with heavier trading behind it.

Sequencing Q2 beat + NovaSeq X 83% of high-throughput gigabases + FY26 guide raised — 91% TTM on the commercial-adoption inflection.

Illumina is the DNA-sequencing leader whose Q2 print delivered a decisive beat — revenue up 9.4%, adjusted EPS up 10%, and full-year 2026 guidance raised. Up 91% year-over-year and pushing 88% of the 52-week range on the specific NovaSeq X commercial-adoption inflection.

  • The Q2 print was decisive: revenue of $1.16B beat the $1.13B estimate (+9.4% YoY) and adjusted EPS of $1.31 beat $1.23 (+10% YoY) — the specific combination that validates the multi-year sequencing-cycle recovery bulls have been modeling.
  • The NovaSeq X adoption is the load-bearing commercial signal: NovaSeq X now represents 83% of high-throughput gigabases shipped (92% research, 78% clinical) and 59% of consumables revenue — the specific mix-shift metric that reflects durable customer adoption at the specific product-line that carries the highest margins.
  • The FY26 guide raise is the specific forward-looking signal: raising FY26 revenue to $4.60-$4.64B and EPS to $5.30-$5.40 reflects specific multi-quarter visibility — the type of guide raise that keeps the +91% run intact.
  • The insider tape is a light offset: officer Michael Sullivan's F-InKind of $900K reflects specific compensation-related activity rather than a directional call — worth noting but not sized to override the fundamental print.

Coming into Oct 29 earnings, the tape needs continued 9%+ revenue growth, sustained NovaSeq X consumables ramp, and any specific clinical-adoption commentary given the 78%-of-clinical-market metric. A clean beat plus reaffirmed FY guide extends the trend past current highs; any competitive-share loss to Ultima Genomics or Element Biosciences is what would compress the just-elevated 33x P/E multiple.

Agrees with X sentimentAgree with the fully-bullish read — the Q2 print, NovaSeq X adoption metrics, and FY26 guide raise are all real, aligned catalysts. The monthly red-resistance-band-consolidation X mentions is a real technical caution but doesn't override the fundamental setup.

What to watch: Oct 29 Q3 earnings — continued 9%+ revenue growth, sustained NovaSeq X consumables ramp, and specific clinical-adoption commentary. Any competitive-share loss to Ultima Genomics or Element Biosciences compresses the just-elevated 33x P/E multiple.

On the calendar: 2026-10-29 — Q3 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment7 posts analyzed · as of 2026-08-06

Illumina chatter is squarely bullish. Q2 revenue $1.16B (+9.4% YoY) beat $1.13B est, adj EPS $1.31 vs $1.23 est (+10% YoY), FY26 revenue raised to $4.60-4.64B and EPS to $5.30-5.40. NovaSeq X now 83% of high-throughput gigabases shipped (92% research, 78% clinical) and 59% of consumables revenue. New 52-week highs. Technicians see monthly red resistance band as expected consolidation. Broadly upbeat.

Read the AI verdict + X sentiment for $ILMN

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Makes DNA sequencing instruments, consumables, and arrays that underpin genomics research, oncology diagnostics, and reproductive health testing globally.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Diagnostics & Research sits in its cycle right now — and what that implies for $ILMN.

Medical - Diagnostics & Research · Healthcare

No material change from last week — pharma R&D spending is recovering and CDMO demand is growing as drug pipelines advance toward clinical trials.

What this means for $ILMN

Neutral — Makes DNA sequencing instruments, consumables, and arrays that underpin genomics research, oncology diagnostics, and reproductive health testing globally; limited read-through from medical - diagnostics & research macro dynamics to this specific revenue mix.

Industry benchmark

21-name peer basket
+34.6%YTD
+78.7%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
33.2How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
13.6%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
21.5%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
3.6%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
6.3Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
34.0%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
67.7%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
1.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Jul 30, 2026$1.31$1.23+6.5%
Q1 2026Apr 30, 2026$1.15$1.05+9.5%
Q4 2025Feb 5, 2026$1.35$1.24+8.9%
Q3 2025Oct 30, 2025$1.34$1.17+14.5%
Next earningsThu, Oct 29·consensus EPS $1.38

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$1.1B+4.8%68.2%21.3%$0.88$251.0M
Q4 FY25$1.2B+5.1%67.1%22.2%$2.18$267.0M
Q3 FY25$1.1B+0.3%67.6%21.3%$0.98$260.0M
Q2 FY25$1.1B-4.9%67.8%21.0%$1.50$211.0M

Forward consensus

5-year forecast · up to 14 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$4.6B$4.6B – $4.6B$5.24$5.16 – $5.2713
FY27$4.8B$4.8B – $5.0B$5.92$5.63 – $6.2113
FY28$5.2B$5.0B – $5.6B$6.89$6.52 – $7.8314
FY29$5.6B$5.5B – $5.8B$7.86$7.71 – $8.187
FY30$5.9B$5.8B – $6.1B$8.77$8.59 – $9.1210

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.5×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.86%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+4.1%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+32.1%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 147.7M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.7% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.465-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellAug 5Keith A. MeisterDirector283.3K sh$56.5MSellAug 4Keith A. MeisterDirector457.9K sh$91.6MSellJul 30Scott M DaviesChief Legal Officer615 sh$123KSellJun 25Scott M DaviesChief Legal Officer615 sh$111KSellJun 5Patricia LeckmanSVP, Chief People Officer783 sh$127KSellJun 2Patricia LeckmanSVP, Chief People Officer784 sh$127KSellJun 1Keith A. MeisterDirector219.5K sh$35.9MSellMay 29Scott D EricksenVP, Chief Accounting Officer500 sh$80KSellMay 29Keith A. MeisterDirector214.6K sh$35.1MSellMay 29Scott M DaviesChief Legal Officer615 sh$98K
1–10 of 13
+ 17 other (12 awards · 2 inthemoneys · 2 others · 1 inkind) in window

See when $ILMN insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KAgreement terminatedAug 138-K — Item 1.01: Material agreement · Item 1.02: Agreement terminated · Item 2.03: Material debt obligation
3New insider — initial holdingsAug 113
AI summary

Illumina (ILMN) filed a Form 3 initial statement of beneficial ownership for its Chief Legal Officer. The filing records the CLO's initial holdings in Illumina common stock as required upon appointment.

3New insider — initial holdingsJul 293
AI summary

An insider (Amount or Number of Shares Explanation of Responses: No secur) at ILMN (ILMN) filed a Form 3 on 2026-07-29 reporting initial or updated beneficial ownership. This is a routine insider reporting disclosure required within 10 days of becoming a 10%+ holder or new officer/director. It has limited standalone market impact but establishes the baseline for tracking future insider transactions.

3New insider — initial holdingsJun 233
AI summary

Daniel Skovronsky, MD/PhD (director, San Diego) filed a Form 3 initial beneficial ownership statement for Illumina as of June 16, 2026. Administrative disclosure.

8-KOfficer or director changeJun 238-K — Item 5.02: Officer or director change
AI summary

Illumina's Board expanded from 9 to 10 members and appointed Daniel Skovronsky, MD/PhD as an independent director effective June 16, 2026, with no third-party arrangement and no related transactions. Addition of a scientifically credentialed independent director.

8-KShareholder voteMay 268-K — Item 5.07: Shareholder vote
AI summary

Illumina's 2026 Annual Meeting on May 21, 2026 elected all 9 director nominees for one-year terms (Caroline Dorsa, Scott Gottlieb, David King, Keith Meister, Anna Richo, Philip Schiller, Susan Siegel, Jacob Thaysen, Scott Ullem), ratified Ernst and Young as independent auditor, and approved the advisory NEO compensation vote. Routine annual meeting; all nominees elected and auditor ratified.

3New insider — initial holdingsMay 223
AI summary

David P. King (director, San Diego CA) filed a Form 3 initial beneficial ownership statement for Illumina as of May 21, 2026. Administrative disclosure for newly reporting Illumina director.

8-KOfficer or director changeApr 28-K — Item 5.02: Officer or director change · Item 7.01: Press release / Reg FD
+ 14 other (4 13Gs · 2 routine 8-Ks · 2 10-Qs · 2 proxys) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

BMRN vs. ILMN: Which Stock Is the Better Value Option?zacks.com·3d agoIllumina (ILMN) is a Top-Ranked Growth Stock: Should You Buy?zacks.com·4d agoEmpowered Funds LLC Increases Stock Holdings in Illumina, Inc. $ILMNdefenseworld.net·8d agoWhat Makes Illumina (ILMN) a New Strong Buy Stockzacks.com·8d agoHere's Why Illumina (ILMN) is a Strong Momentum Stockzacks.com·10d ago

More in Medical - Diagnostics & Research

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$NEO$TWST$NTRA$A$TMO$PSNL$GH$DHR
Voices on X · last 7 days

No standout posts about $ILMN on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport